Coreline Soft, a company developing medical software printing three-dimensional images, said Monday that it has agreed to supply AVIEW LCS for screening lung cancer to the pan-European lung cancer screening from August.

The company will provide its solution for running the EU Lung Cancer Screening (LCS) Trial, called the “4-IN THE LUNG RUN,” in the U.K., France, Italy, Germany, Netherlands, and Spain for four years. About 26,000 patients carrying a high risk of lung cancer will undergo screening based on NELSON trial results.

Besides the EU’s drive for the project, the company will also supply the solution to three hospitals in Germany’s Hanse lung cancer screening project, a separate national program involving 5,000 people for two years.

AVIEW LCS has been used by more than 100 medical institutions in Korea, including the National Cancer Center, Seoul National University Hospital, and the National Medical Center, as the official solution for national lung cancer screening since 2017.

The solution helps health providers in the entire process of reading images, from detection, automatic measurement, and follow-up of each nodule to comparison between nodules and automated reporting based on Lung-RADS, which is a lung imaging reporting and data system. As a result, a single screening can check for lung cancer, chronic obstructive pulmonary disease, and cardiovascular disease simultaneously with a single computed tomography image.

The technology collecting lung cancer screening images in the cloud-based system and receiving readings allowed reduced deviations in screening results across the country and raised accuracy.

Coreline Soft has also signed a deal with the Institute for Diagnostic Accuracy (iDNA) to co-develop lung screening cancer software, trying to meet its goal of accelerating high-quality implementation and making lung cancer screening accessible for those who benefit.

According to the Health Insurance Review and Assessment Service, the number of hospitalized patients with lung cancer rose by 36 percent in four years, from 73,765 in 2015 to 100,371 in 2019

Besides, a study published in the Journal of American Medical Association  predicted that breast and lung cancers and melanoma would be the most common cancer by 2040, warning that lung cancer would also become the leading cause of cancer-related deaths.

“Europe has been paying attention to the Korean lung cancer diagnosis system’s accumulation. We expect the domestic system will be a role model for lung cancer screening as K-screening, based on accomplishments made in chest screening solutions beyond lung cancer,” a Coreline Soft official said.